Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - david+fitzgerald
2
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
EGFRvIII Antibodies for the Treatment of Human Cancer
Abstract: Epidermal growth factor receptor variant III (EGFRvIII) is a variant of EGFR that is an excellent target for immunotherapy because of its expression in cancer cells and not in normal cells. Inventors from the National Cancer Institute (NCI) have isolated seven mouse monoclonal antibodies that bind to the human EGFRvIII but not wildtype EGFR....
Published: 4/8/2024
|
Inventor(s):
David Fitzgerald
,
Antonella Antignani
,
Eric Ho
,
Robert Sarnovsky
Keywords(s):
ADC
,
Antibody-drug Conjugate
,
CAR
,
chimeric antigen receptor
,
EGFR
,
EGFRvIII
,
Epidermal Growth Factor Receptor
,
Epidermal growth factor receptor variant III
,
FitzGerald
,
Recombinant Immunotoxins
,
RITs
Category(s):
Application > Therapeutics
,
TherapeuticArea > Oncology
,
Collaboration Sought > Collaboration
,
Collaboration Sought > Licensing
Efficient Cell-Free Production of Papillomavirus Gene Transfer Vectors
Abstract: Papillomavirus pseudoviruses that comprise the L1/L2 capsid proteins can package a wide variety of non-viral DNA plasmids and deliver the packaged genetic material to cells. This function makes them attractive candidates as targeted gene delivery vehicles. Current methods for the efficient production of papillomavirus pseudoviruses require...
Published: 4/8/2024
|
Inventor(s):
John Schiller
,
Carla Correia Cerqueira
,
Patricia Day
,
Douglas Lowy
,
David Fitzgerald
Keywords(s):
CANCER
,
cancer therapeutic
,
cell-free production
,
papillomavirus
,
Schiller
,
therapeutic
,
tumor therapy
,
Vaccine
,
vectors
,
virus based gene transfer vectors
Category(s):
Application > Therapeutics
,
Collaboration Sought > Licensing
,
Collaboration Sought > Collaboration
,
TherapeuticArea > Infectious Disease
,
TherapeuticArea > Oncology